EBITDA $100M is def "possible", but you've not mentioned a timeframe.
Let's just get to +$1 first - without removing items that shouldn't be removed.
Derm needs to at least hold fat. The first 3 months were REALLY strong, month 4, not so much.
Management are doing the right 'things', but if someone is questioning why the share price is taking a breather; let's be realistic, we need to see continual and sustained growth as revenue needs to get well above $400m before we are cashflow POS and EBITDA +
Ann: Mayne Pharma presentation at JP Morgan Healthcare Conference, page-21
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.40 |
Change
0.140(3.29%) |
Mkt cap ! $374.3M | |||
| Open | High | Low | Value | Volume |
| $4.25 | $4.43 | $4.25 | $618.9K | 141.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 2957 | $4.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.41 | 968 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |